
Are Mega-Mergers Back?
Pharmaceutical industry consolidation faces significant skepticism as analysts question the logic behind a potential AstraZeneca and Bristol-Myers Squibb merger, citing AstraZeneca’s robust organic growth and the risk of absorbing looming patent cliffs. Beyond sector-specific deals, the broader market grapples with a d...
